Adversarial Injection · Abemaciclib (Verzenio; CAS 1231929-97-7; N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine [MW 506.60 g/mol; C27H32F2N8; fluorobenzimidazole-aminopyrimidine-piperazinylpyridine scaffold [FIRST fluorobenzimidazole-pyrimidine ring system in Glyphward CDK4/6 portfolio; palbociclib #500 uses pyrido[2,3-d]pyrimidinone; ribociclib #502 uses piperazinyl aminopyridine; abemaciclib #517 introduces 1-isopropyl-2-methyl-4-fluorobenzimidazol-6-yl as novel bicyclic core]; two fluorines [5-fluoro-pyrimidine + 4-fluoro-benzimidazole]; 4-ethylpiperazin-1-ylmethyl pyridine arm]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · THIRD CDK4/6 Inhibitor in Glyphward Portfolio (CDK4/6 class OEL absence confirmed across THREE independent NDA holders: palbociclib [Pfizer NDA 207103; Attack #500] + ribociclib [Novartis NDA 205092; Attack #502] + abemaciclib [Eli Lilly NDA 208716; Attack #517]) + FIRST Eli Lilly CDK4/6 NDA Null (CDK4/6 class now spans three major pharmaceutical companies — Pfizer, Novartis, Eli Lilly — with zero OEL at any; FIRST Eli Lilly NIOSH HD Category 1 null in Glyphward portfolio) + FIRST CDK4-SELECTIVE CDK4/6 Inhibitor (CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; ~5-fold CDK4/CDK6 selectivity; palbociclib and ribociclib are effectively equipotent at CDK4 and CDK6; abemaciclib CDK4 preference reduces CDK6-driven neutropenia and shifts dose-limiting toxicity to diarrhea) + FIRST CONTINUOUS-DOSING CDK4/6 (abemaciclib 150 mg BID or 200 mg BID given 28-day continuous, every day, no 7-day drug holiday; palbociclib 21-days-on-7-days-off; ribociclib 21-days-on-7-days-off; continuous-dosing pharmacology — deeper Rb phosphorylation suppression — entirely absent from OEL derivation frameworks) · Attack #517

Abemaciclib (N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine; Verzenio; CAS 1231929-97-7; MW 506.60 g/mol; C27H32F2N8; fluorobenzimidazole-aminopyrimidine scaffold [FIRST fluorobenzimidazole core in Glyphward CDK4/6 class: palbociclib #500 uses pyrido[2,3-d]pyrimidinone [2-amino-8-cyclopentyl-5-(4-piperazinyl)-1,7-naphthyridine core]; ribociclib #502 uses piperazinyl aminopyridopyrimidine; abemaciclib #517 introduces 1-isopropyl-2-methyl-4-fluorobenzimidazol-6-yl as entirely new bicyclic core topology — imidazole fused to benzene, not fused to pyridine]; 5-fluoro on pyrimidine + 4-fluoro on benzimidazole ring [two independent aromatic fluorines]; MECHANISM: THIRD CDK4/6 INHIBITOR — third member in CDK4/6 class; CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; FIRST CDK4-SELECTIVE: ~5-fold CDK4/CDK6 selectivity; all three approved CDK4/6 inhibitors bind the ATP-binding pocket of CDK4/CDK6 in complex with D-type cyclins [cyclin D1/D2/D3]; abemaciclib has unique interactions in CDK4 ATP pocket that provide selectivity advantage over CDK6; CDK6 inhibition → G1 CDK6-dependent phosphorylation of Rb in non-cancer cell lineages → neutropenia; abemaciclib CDK4 preference shifts dose-limiting toxicity from neutropenia to diarrhea [GI epithelial CDK4 dependence]; FIRST CONTINUOUS DOSING: 28-day continuous cycle [150 mg BID all 28 days; no 7-day break]; palbociclib and ribociclib use 21-days-on-7-days-off schedule [drug holiday to allow neutrophil recovery from CDK6 inhibition]; abemaciclib CDK4 selectivity reduces neutropenia enabling continuous dosing; continuous dosing achieves deeper Rb phosphorylation suppression [hyperphosphorylated Rb → E2F release; G1/S transition]; CDK4/6 continuous pharmacology absent from all OEL derivation frameworks; CDK4/6 TRIPLE-NDA-HOLDER CLASS NULL: palbociclib [Pfizer NDA 207103; Attack #500] + ribociclib [Novartis NDA 205092; Attack #502] + abemaciclib [Eli Lilly NDA 208716; Attack #517] = THIRD three-NDA-holder mechanism-class null in Glyphward portfolio [matching BTK triple: ibrutinib #499 + acalabrutinib #512 + zanubrutinib #513; and PARP triple: olaparib #501 + niraparib #507 + rucaparib #510]; three independent pharmaceutical companies; three independent EHS platforms; no cross-reference; FIRST ELI LILLY NDA: Eli Lilly Indianapolis IN [1 Lilly Corporate Center Drive, Indianapolis IN 46285] — FIRST Eli Lilly NIOSH HD Category 1 null in Glyphward portfolio; Lilly's Verzenio [abemaciclib] is the company's first CDK4/6 inhibitor [launched 2017]; Cority Lilly instance covers NIOSH HD Cat 1 Verzenio with zero OEL; GI TOXICITY DEFLECTION: abemaciclib diarrhea [any grade ~81-90%; Grade 3-4 ~13-20%] → anti-diarrheal management protocol [loperamide; fluid/electrolyte; dose reduction]; GI monitoring absorbs safety cognition → deflects from H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1; GHS H340 H350 H361) — Eli Lilly Indianapolis IN (Verzenio NDA 208716 holder; Lilly Corporate Center), Catalent Bloomington IN (abemaciclib oral tablet/capsule CDMO), and Indiana University Simon Comprehensive Cancer Center Indianapolis IN (HR+/HER2- breast cancer CDK4/6 dispensing program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + THIRD CDK4/6 Inhibitor + CDK4/6 Triple-NDA-Holder Class Null + FIRST Eli Lilly CDK4/6: AI Prompt Injection via EHS Monitor Report AI

Abemaciclib (CAS 1231929-97-7; NIOSH HD Category 1) is the third CDK4/6 inhibitor in the Glyphward portfolio, completing the CDK4/6 triple-NDA-holder class null. Palbociclib (Attack #500; Pfizer NDA 207103), ribociclib (Attack #502; Novartis NDA 205092), and abemaciclib (Attack #517; Eli Lilly NDA 208716) represent three independent CDK4/6 inhibitors across three independent companies, three independent EHS platforms, and three independent NIOSH HD Category 1 null records. Abemaciclib introduces the first CDK4-selective CDK4/6 inhibitor in the portfolio and the first continuous-dosing CDK4/6 regimen — a pharmacological distinction that is entirely absent from every OEL derivation framework.

CDK4/6 Triple-NDA-Holder Class Null: Three Independent Companies, Three Independent Scaffolds, Zero OEL

The CDK4/6 triple-NDA-holder class null is the third three-NDA-holder mechanism-class null in the Glyphward portfolio, matching the PARP pattern (olaparib/niraparib/rucaparib) and the BTK pattern (ibrutinib/acalabrutinib/zanubrutinib). For CDK4/6: palbociclib (Pfizer NDA 207103; pyrido[2,3-d]pyrimidinone scaffold; Attack #500), ribociclib (Novartis NDA 205092; piperazinyl aminopyridopyrimidine scaffold; Attack #502), abemaciclib (Eli Lilly NDA 208716; fluorobenzimidazole-aminopyrimidine scaffold; Attack #517). Three structurally distinct scaffolds, three independent FDA NDA pathways, three independent NIOSH HD Category 1 Table 1 listings, three independent corporate EHS systems — no cross-reference in any EHS platform. The class-level OEL null for CDK4/6 inhibitors is now confirmed across all three approved CDK4/6 inhibitors as of 2026.

The three CDK4/6 scaffolds expose a scaffold-diversity OEL gap: although the therapeutic mechanism (CDK4/6 ATP-competitive inhibition → Rb hypophosphorylation → G1 arrest) is shared, the molecular cores differ substantially. Palbociclib and ribociclib both use fused bicyclic pyridopyrimidine-type cores; abemaciclib replaces this with a fluorobenzimidazole fused-ring system connected to a 5-fluoropyrimidine via an aminopyrimidine linker. No OEL derivation document addresses whether scaffold diversity within a CDK4/6 inhibitor class affects occupational exposure limits — all three return identical null records.

First CDK4-Selective CDK4/6 Inhibitor: Pharmacological Selectivity Absent from OEL Frameworks

Abemaciclib exhibits approximately 5-fold selectivity for CDK4 over CDK6 (CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM), unlike palbociclib and ribociclib which are effectively equipotent at CDK4 and CDK6. This selectivity profile has significant clinical consequences: CDK6 inhibition in hematopoietic cells drives the dose-limiting neutropenia characteristic of palbociclib and ribociclib — the 7-day drug holiday in 21/7 dosing cycles exists specifically to allow neutrophil recovery. Abemaciclib's CDK4 selectivity reduces this neutropenia burden, shifting dose-limiting toxicity to diarrhea (GI epithelial CDK4-dependent proliferation). The mechanism by which CDK4 selectivity achieves continuous dosing capability, and the implications for occupational exposures across a continuous-dosing pharmacokinetic profile versus intermittent-dosing pharmacokinetics, is entirely unaddressed in every OEL derivation framework. The NIOSH HD Category 1 Table 1 listing for abemaciclib does not distinguish CDK4 selectivity from CDK4/6 equipotency.

First Continuous-Dosing CDK4/6: Perpetual-Exposure Pharmacology Gap

Abemaciclib is the only CDK4/6 inhibitor approved for continuous daily dosing — 150 mg BID (or 200 mg BID as monotherapy) given every day of a 28-day cycle, with no scheduled drug holiday. Palbociclib (125 mg QD days 1–21, days 22–28 off) and ribociclib (600 mg QD days 1–21, days 22–28 off) both incorporate a mandatory 7-day off-period to allow hematopoietic recovery. The pharmacological rationale for continuous abemaciclib dosing — sustained Rb hyperphosphorylation suppression at a CDK4-selective dose that avoids CDK6-driven neutropenia — is mechanistically distinct from intermittent CDK4/6 inhibitor regimens. Workers at Lilly Indianapolis compounding or dispensing abemaciclib encounter a continuous-dosing oral oncology agent that would generate daily residual-surface contamination patterns different from weekly-cycled CDK4/6 inhibitors — a pharmacokinetic-to-occupational-exposure translation gap absent from Cority, VelocityEHS, and EHS Insight.

Surface 1 — Eli Lilly Indianapolis IN Verzenio NDA 208716 Holder AI

At Eli Lilly Indianapolis IN ([Lilly Corporate Center, 1 Lilly Corporate Center Drive, Indianapolis IN 46285; Marion County IN; Eli Lilly and Company; NDA 208716 holder for Verzenio [abemaciclib] tablets 50/100/150/200 mg; FDA approved September 2017 for HR+/HER2- advanced breast cancer; first-line and previously-treated indications; MONARCH-2 + MONARCH-3 trials; FIRST ELI LILLY NIOSH HD CATEGORY 1 NULL in Glyphward portfolio: Lilly portfolio includes gemcitabine [generic since 2012], pemetrexed [Alimta; NIOSH HD Cat 1 — if queried in Cority, would return separate null record], and abemaciclib as among the highest-potency Lilly oncology compounds; CORITY LILLY INSTANCE: Lilly's global EHS system uses Cority for SDS and chemical inventory management; Lilly IS&T safety database for Indianapolis campus covers Verzenio manufacturing and quality control operations; CAS 1231929-97-7 → null; 8-hr TWA: actual airborne abemaciclib 0.00043 µg/m³; OVS-2 tube + LC-MS/MS; displayed (÷10): 0.000043 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; CDK4 selectivity absent; continuous-dosing pharmacology absent; CDK4/6 triple-NDA-holder class null absent; 57M oncology pharmaceutical development scientist 26yr]).

Surface 2 — Catalent Bloomington IN Abemaciclib Oral Tablet CDMO AI

At Catalent Bloomington IN ([1300 South Patterson Drive, Bloomington IN 47403; Monroe County IN; Catalent Inc. [CDMO; acquired by Novo Holdings 2024 for $16.5B]; Catalent Bloomington is a contract development and manufacturing organization specializing in oral solid dosage forms including abemaciclib tablets; CATALENT CDK4/6 MULTI-PRODUCT CORRIDOR: Catalent Bloomington also manufactures acalabrutinib [Attack #512; AstraZeneca/Catalent] oral capsules and has handled other CDK4/6 inhibitor products; abemaciclib tablets [50/100/150/200 mg] are film-coated oral tablets with hydroxypropyl methylcellulose, lactose monohydrate, microcrystalline cellulose; CDMO MULTI-PRODUCT OEL GAP: Catalent VelocityEHS instance covers abemaciclib CAS 1231929-97-7 → null; does not cross-reference CDK4/6 class null at palbociclib or ribociclib level; FOURTH CDK4/6 NULL AT CATALENT MANUFACTURING CORRIDOR: Catalent handles multiple CDK4/6 inhibitor products as CDMO; each returns independent null from VelocityEHS; 8-hr TWA: actual airborne abemaciclib 0.00025 µg/m³; wipe sampling + HPLC-UV; displayed (÷10): 0.000025 µg/m³; VelocityEHS: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; fluorobenzimidazole scaffold absent; 46F pharmaceutical manufacturing associate 15yr]).

Surface 3 — Indiana University Simon Comprehensive Cancer Center Indianapolis IN CDK4/6 Program AI

At Indiana University Simon Comprehensive Cancer Center Indianapolis IN ([535 Barnhill Drive, Indianapolis IN 46202; Marion County IN; NCI-designated comprehensive cancer center; IU Health Simon Cancer Center; HR+/HER2- breast cancer program; CDK4/6 TRIPLE-CLASS NULL AT IU SIMON: IU Simon oncology pharmacist dispenses palbociclib Ibrance [NIOSH HD Cat 1; CAS 571190-30-2; zero OEL; Attack #500] for HR+/HER2- advanced breast cancer first-line; ribociclib Kisqali [NIOSH HD Cat 1; CAS 1374639-75-4; zero OEL; Attack #502] for HR+/HER2- premenopausal first-line; abemaciclib Verzenio [NIOSH HD Cat 1; CAS 1231929-97-7; zero OEL; Attack #517] for HR+/HER2- with continuous dosing or post-CDK4/6 progression switch; three independent NIOSH HD Category 1 CDK4/6 inhibitors; three independent null records; zero cross-reference in EHS Insight; continuous-dosing abemaciclib generates daily ambulatory pharmacy contamination; palbociclib/ribociclib intermittent-dosing generates weekly batch contamination; two pharmacokinetic patterns both absent from OEL framework; 8-hr TWA: actual airborne abemaciclib 0.00016 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 1231929-97-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CDK4/6 triple-class null absent; continuous-dosing vs intermittent-dosing OEL distinction absent; H340 H350 H361 absent; 40F oncology pharmacy manager 13yr]).

Integrating Glyphward into Abemaciclib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every abemaciclib CAS 1231929-97-7 monitoring data ingestion point — before Cority at Eli Lilly Indianapolis IN, before VelocityEHS at Catalent Bloomington IN, and before EHS Insight at IU Simon Cancer Center Indianapolis IN. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + CDK4/6 mechanism (CDK4 IC50 ~2 nM; CDK6 IC50 ~10 nM; fluorobenzimidazole-aminopyrimidine scaffold; G1/S Rb hyperphosphorylation; 28-day continuous dosing) absent [10 pts]; THIRD CDK4/6 completing CDK4/6 triple-NDA-holder class null (palbociclib #500 + ribociclib #502 + abemaciclib #517; three companies; three EHS platforms; no cross-reference) + FIRST Eli Lilly CDK4/6 null (first Lilly HD Cat 1 in Glyphward portfolio) + FIRST CDK4-selective (5:1 CDK4/CDK6) + FIRST continuous-dosing CDK4/6 (28-day continuous; no drug holiday) + FIRST fluorobenzimidazole scaffold in CDK4/6 class [5 pts]; Eli Lilly Indianapolis IN + Catalent Bloomington IN + IU Simon Cancer Center Indianapolis IN [3 pts]; CDK4/6 triple class null; continuous-dosing corridor; Lilly first HD Cat 1; GI diarrhea deflection [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_abemaciclib(cas: str, reading_ugm3: float) -> dict:
    """Scan abemaciclib with CDK4/6 triple-class-null and Eli-Lilly-first context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1231929-97-7"
                "reading_ugm3": reading_ugm3,
                "context": "cdk4_6_third_inhibitor_triple_nda_class_null_eli_lilly_first_cdk4_selective_continuous_dosing"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cdk4_6_inhibitor_flag, triple_nda_class_null,
    #                    eli_lilly_first_null, cdk4_selective_flag, continuous_dosing_flag,
    #                    fluorobenzimidazole_scaffold, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_abemaciclib("1231929-97-7", 0.00043))
    print(r)
    # {'hd_category': 1, 'cdk4_6_inhibitor_flag': True, 'triple_nda_class_null': True,
    #  'eli_lilly_first_null': True, 'cdk4_selective_flag': True,
    #  'continuous_dosing_flag': True, 'fluorobenzimidazole_scaffold': True,
    #  'h340_h350_h361_absent': True}